To include your compound in the COVID-19 Resource Center, submit it here.

Intercept details safety initiatives for Ocaliva, reiterates NASH plans

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced plans to address an FDA drug safety communication regarding the company’s primary biliary cholangitis (PBC) drug Ocaliva obeticholic acid (DSP-1747). The company also reiterated its Phase III plans for Ocaliva to treat non-alcoholic

Read the full 384 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE